Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Plus Therapeutics Inc (PSTV)

Plus Therapeutics Inc (PSTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,340
  • Shares Outstanding, K 137,429
  • Annual Sales, $ 5,820 K
  • Annual Income, $ -12,980 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 0.85
  • Price/Sales 12.80
  • Price/Cash Flow N/A
  • Price/Book 15.10
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.28
  • Most Recent Earnings $-0.04 on 10/30/25
  • Next Earnings Date 03/26/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.03
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.03
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +95.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4700 +0.02%
on 01/13/26
0.7000 -32.84%
on 12/15/25
-0.2137 (-31.25%)
since 12/12/25
3-Month
0.4559 +3.11%
on 11/17/25
0.7554 -37.77%
on 12/12/25
-0.2070 (-30.57%)
since 10/13/25
52-Week
0.1634 +187.70%
on 06/18/25
2.3099 -79.65%
on 03/07/25
-0.6699 (-58.76%)
since 01/13/25

Most Recent Stories

More News
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.  (Nasdaq:  PSTV ) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and...

PSTV : 0.4701 (-4.06%)
Novel Modalities Drive $668B Precision Oncology Expansion

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is projected to reach US$668.26 billion by 2034[1], as investors increasingly...

ONCY : 1.0000 (+0.85%)
PSTV : 0.4701 (-4.06%)
IMNM : 20.14 (-2.09%)
BCYC : 6.49 (-1.37%)
CELC : 104.21 (-0.29%)
Plus Therapeutics Expands CNSide Assay Platform to State of California

HOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc.  (Nasdaq:  PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical...

PSTV : 0.4701 (-4.06%)
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.  (Nasdaq:  PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics...

PSTV : 0.4701 (-4.06%)
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent...

PSTV : 0.4701 (-4.06%)
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...

PSTV : 0.4701 (-4.06%)
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 0.4701 (-4.06%)
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of  Plus Therapeutics, Inc.  (Nasdaq:  PSTV ) (“Plus” or the “Company”), announced today that...

PSTV : 0.4701 (-4.06%)
HUM : 273.96 (-0.95%)
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

HOUSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...

PSTV : 0.4701 (-4.06%)
Plus: Q3 Earnings Snapshot

Plus: Q3 Earnings Snapshot

PSTV : 0.4701 (-4.06%)

Business Summary

Plus Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing treatments for cancer and other diseases primarily in the United States. The company's product candidate consists of DocePLUS which are in clinical stage. Plus Therapeutics Inc., formerly known as Cytori Therapeutics...

See More

Key Turning Points

3rd Resistance Point 0.5267
2nd Resistance Point 0.5154
1st Resistance Point 0.4927
Last Price 0.4701
1st Support Level 0.4587
2nd Support Level 0.4474
3rd Support Level 0.4247

See More

52-Week High 2.3099
Fibonacci 61.8% 1.4899
Fibonacci 50% 1.2366
Fibonacci 38.2% 0.9834
Last Price 0.4701
52-Week Low 0.1634

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar